Bcwm LLC Invests $1.98 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bcwm LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, HoldingsChannel reports. The firm purchased 18,766 shares of the medical equipment provider’s stock, valued at approximately $1,982,000.

Several other large investors also recently modified their holdings of the stock. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet during the 4th quarter worth $25,000. Dunhill Financial LLC grew its stake in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the period. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet during the third quarter worth approximately $35,000. Kentucky Trust Co acquired a new stake in Zimmer Biomet in the 4th quarter valued at $39,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth about $40,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $112.21 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $131.61. The stock has a market capitalization of $22.34 billion, a PE ratio of 25.22, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The business has a 50 day simple moving average of $107.18 and a 200-day simple moving average of $107.02.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the company earned $2.20 earnings per share. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ZBH shares. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Truist Financial reissued a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $124.15.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.95% of the stock is owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.